You know the feeling – the itchy eye that is just begging to be scratched. Before you start rubbing your eyes, you may want to think twice about the potential consequences. While eye rubbing may seem ...

Please provide your email address to receive an email when new articles are posted on . Eye rubbing can be influenced by a number of factors including allergies, ophthalmic conditions and stress.

Rachel Williams has been an editor for nearly two decades. She has spent the last five years working on small business content to help entrepreneurs start and grow their businesses. She’s well-versed ...

If you've ever been half asleep on the couch, rubbing your eyes routinely, you're not alone; it's a universal move. Babies do it. Adults do it. People pretending they're "not tired" do it the most.

Arrhythmias, or irregular heart rhythms, are common complications of HCM. The thickened heart muscle disrupts the electrical pathways that coordinate heartbeat, leading to arrhythmias. Atrial ...

FPC is known for its expertise in payroll reconstruction, agency notice resolution, Employee Retention Credit (ERC) filings, and merger & acquisition compliance. By integrating FPC’s capabilities, HCM ...

MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...

Oracle yesterday announced more than a dozen AI agents that will be available as part of its Fusion HCM application, complementing the twelve already announced earlier this year, along with many ...

Oracle Corp. today announced a series of new agentic artificial intelligence extensions to its Fusion Cloud Human Capital Management suite, bringing the number of agents in the application to more ...

Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. We conducted a phase 3, ...

MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...

In patients with nonobstructive hypertrophic cardiomyopathy (nHCM) treatment with a cardiac myosin inhibitor does not seem to yield significant improvements in quality-of-life (QoL) or oxygen ...